Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
14 Juni 2021 - 3:15PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that data will be presented during two plenary sessions
at the International Society for Stem Cell Research 2021 Virtual
Annual Meeting, to be held Monday, June 21 through Saturday, June
26.
Chuck Murry, M.D., Ph.D., Sana’s Head of Cardiometabolic Cell
Therapy, will be presenting “Genome Editing to Eliminate
Engraftment Arrhythmia during Heart Regeneration” during the
conference’s first plenary session, the Presidential Symposium
titled ‘What's in a Germ Layer?’ The session will begin on Monday,
June 21 at 9:30 a.m. ET and will end at 11:45 a.m. ET.
Sonja Schrepfer, M.D., Ph.D., Sana’s Head of Hypoimmune
Platform, will be speaking during the sixth plenary session on
Cellular Therapy and Tissue Engineering, highlighting the Clinical
Applications conference theme. She will present “Protecting
Transplanted Stem Cells from Immune Rejection.” The plenary session
will begin on Saturday, June 26 at 9:30 a.m. ET and will end at
11:00 a.m. ET.
Both presentations will be rebroadcast at 9:30 p.m. ET on the
day of their presentation and will be available to ISSCR
registrants for on-demand viewing through July 31, 2021.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are more than 300
people working together to create an enduring company that changes
how the world treats disease. Sana has operations in Seattle,
Cambridge, and South San Francisco. For more information about Sana
Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for its development programs, product
candidates and technology platforms, including its pre-clinical,
clinical and regulatory development plans and timing expectations;
expectations for the presentation or publication of data, including
in medical or scientific journals; and the content of the Company’s
presentations at the International Society for Stem Cell Research
2021 Virtual Annual Meeting. All statements other than statements
of historical facts contained in this press release, including,
among others, statements regarding the Company’s strategy,
expectations, cash runway and future financial condition, future
operations, and prospects, are forward-looking statements. In some
cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,”
“intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
“predict,” “seek,” “should,” “target,” “will,” “would” and other
similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other
comparable terminology. The Company has based these forward-looking
statements largely on its current expectations, estimates,
forecasts and projections about future events and financial trends
that it believes may affect its financial condition, results of
operations, business strategy and financial needs. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. These statements are subject to risks and
uncertainties that could cause the actual results to vary
materially, including, among others, the risks inherent in drug
development such as those associated with the initiation, cost,
timing, progress and results of the Company’s current and future
research and development programs, preclinical and clinical trials,
as well as the economic, market and social disruptions due to the
ongoing COVID-19 public health crisis. For a detailed discussion of
the risk factors that could affect the Company’s actual results,
please refer to the risk factors identified in the Company’s SEC
reports, including but not limited to its Annual Report on Form
10-K dated March 24, 2021 and Quarterly Report on Form 10-Q dated
May 5, 2021. Except as required by law, the Company undertakes no
obligation to update publicly any forward-looking statements for
any reason.
All product and company names herein may be trademarks of their
registered owners.
Investor Relations:Nicole
Keithinvestor.relations@sana.com
Media:Morgan Warners, Finsbury Glover
Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Okt 2023 bis Okt 2024